On October 15, 2026, CanSino Biologics Inc. ("CanSinoBIO") held its annual Scientific Advisory Board (SAB) meeting at Vaccinopolis, University of Antwerp, Belgium. The meeting brought together experts in vaccine research and development, clinical research, and public health, alongside CanSinoBIO's senior management and R&D teams. Discussions focused on the progress of the company's innovative vaccine pipeline, global clinical development and regulatory strategies, and evolving global disease prevention needs, providing scientific insights to support CanSinoBIO's continued innovation and international development.

CanSinoBIO held its annual Scientific Advisory Board (SAB) meeting  at Vaccinopolis, University of Antwerp, Belgium

The meeting was attended by Dr. George Siber, Chair of CanSinoBIO's Scientific Advisory Board, and SAB members Dr. Luis Barreto, Prof. Pierre Van Damme, Prof. David Salisbury, and Prof. Jingren Zhang. CanSinoBIO representatives included Dr. Xuefeng Yu, Chairman and Chief Executive Officer; Dr. ShouBai Chao, Chief Operating Officer; Dr. Tao Zhu, Chief Scientific Officer; Ms. Jeanne Wang, Chief Commercial Officer; Dr. Helen Huihua Mao, Senior Strategic Advisor; and several R&D project leaders. Prof. Joris Vandeputte also participated as a specially invited external expert. Prof. Pierre Van Damme and Dr. Jean-Denis Shu, Senior Vice President of Medical Affairs at CanSinoBIO, co-chaired the meeting.

Dr. Xuefeng Yu, Chairman and Chief Executive Officer

Dr. ShouBai Chao, Chief Operating Officer

Dr. Tao Zhu, Chief Scientific Officer

Ms. Jeanne Wang, Chief Commercial Officer

The meeting featured in-depth discussions on CanSinoBIO's innovative vaccine development programs targeting pertussis, diphtheria and tetanus, poliomyelitis, tuberculosis, meningococcal disease, and pneumococcal disease. Drawing on global disease prevention needs, advances in vaccine technologies, and international clinical experience, participants exchanged perspectives on the development progress of key vaccine candidates, global clinical development and regulatory pathways, and future directions for next-generation vaccines.

Beyond the clinical development and international advancement of the company's existing pipeline, discussions also explored the potential of emerging vaccine technologies. Experts reviewed immunization policies for serogroup B meningococcal disease in the United Kingdom and global polio control practices, examining how innovative vaccine development could be better aligned with real-world public health needs. These discussions provided valuable perspectives to inform CanSinoBIO's future product development and global market strategies.

CanSinoBIO's Scientific Advisory Board serves as an important platform connecting the company with international scientific research, clinical expertise, and global public health priorities. Through sustained engagement with leading experts, the company gains diverse perspectives on scientific innovation, clinical development, regulatory considerations, and disease prevention needs, supporting informed R&D decision-making and long-term technology development.

This year's SAB meeting further strengthened CanSinoBIO's scientific engagement with international experts and provided an opportunity to refine its innovative vaccine development strategies, explore emerging technologies, and identify opportunities for broader international collaboration.

CanSinoBIO will remain committed to addressing unmet needs in disease prevention and strengthening collaboration with research institutions, clinical experts, and public health partners worldwide. By advancing the translation of innovative technologies into vaccines with meaningful public health impact, the company continues to pursue its mission of providing innovative, high-quality, and affordable vaccines globally.

Disclaimer:

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.